Evidence map›Paper›PMID 41993175›Full record

ArticleFrontiers in immunology2026

Case Report: Transverse myelitis following CAR-T cell therapy for post-transplant lymphoproliferative disorder.

Nicolas Desbaillets, Ana Isabel Martín-Quesada, Arthur Mulvey, Marie Le Moine, Eleonora Ghisoni, Raphael Stadelmann, Angela Koutsokera, Eleftheria Kampouri, Vincent Dunet, Andreas F Hottinger and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nicolas DesbailletsMedical Oncology, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Ana Isabel Martín-QuesadaImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Arthur MulveyImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Marie Le MoineImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Eleonora GhisoniImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Raphael StadelmannService of Hematology and Central Laboratory of Hematology, Departments of Oncology and Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Angela KoutsokeraPneumology Service, Pulmonary Transplant Unit, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Eleftheria KampouriInfectious Diseases Service, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Vincent DunetDepartment of Medical Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Andreas F HottingerMedical Oncology, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Petr SzturzMedical Oncology, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Caroline ArberImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Lionel TruebImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Bernhard GentnerImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Blanca Navarro-RodrigoImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of severe, irreversible transverse myelitis following CD19-directed CAR-T cell therapy (axicabtagene ciloleucel) for refractory post-transplant lymphoproliferative disorder (PTLD) in a young female lung-transplant recipient. This case illustrates an emerging neurotoxic complication of CAR-T cell therapy and highlights convergent risk factors including demographics, tumor type and CAR construct. We discuss current evidence of CAR-T-associated myelopathy, its proposed inflammatory and immune-trafficking mechanisms, and the potential contribution of interleukins and chemokines such as IL-1, IL-6, IL-18, CCL-2 and CXCL10 signaling to spinal cord injury. We further address diagnostic challenges, and review current management strategies such as corticosteroids, IL-1 blockade, and IL-6 neutralization. This report underscores the need for heightened vigilance, early imaging, and systematic reporting to improve prevention and treatment of this rare but severe CAR-T-related neurotoxicity.

Indexed as

Immunotherapy, AdoptiveLymphoproliferative DisordersMyelitis, TransverseAdultFemaleHumansChimeric Antigen Receptor T-cell Therapy (CAR-T cell therapy)cytokinesImmune Effector Cell-associated Neurotoxicity Syndrome (ICANS)Post-Transplant Lymphoproliferative Disease (PTLD)transverse myelitis

Identifiers

PMID41993175
PMCPMC13079688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.